BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Research Notes

Adobe Is Growing at Its Fastest Clip in Years. The Stock Trades as If the Party Ended Long Ago.

Moe Alsumidaie by Moe Alsumidaie
August 21, 2026
in Research Notes
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Adobe spent most of the 2010s convincing skeptical investors that giving up one-time software sales for monthly subscriptions was a good idea. The bet paid off spectacularly: a business that once earned a fraction of today’s profits now generates more than $7 billion a year. Then came 2022, a massive bid for design rival Figma, two years of antitrust limbo, a $1 billion breakup fee when regulators killed the deal, and a stock that has spent the time since drifting lower. Today Adobe is growing faster than it has in years, its AI products are gaining real traction, and the share price sits near a decade-low valuation. Those two facts should not coexist. That tension is the story.

In one breath

The 10-Q filed June 15, 2026 shows revenue growing 13% year-over-year, margins holding above a third of every sales dollar, and a forward revenue backlog worth more than three full quarters of current sales. The stock, at $263, trades at roughly half its own decade-long average multiple. The market is pricing Adobe as if growth is about to stall. The filing says it hasn’t. Those two readings cannot both be right, and that disagreement is the story.

What the quarter actually said

Adobe’s fiscal second quarter ended May 29, 2026. Revenue came in at $6.62 billion, up 13% from the same quarter a year earlier, the strongest year-over-year growth rate the company has posted in this part of its recent cycle. The overwhelming majority came from subscriptions, meaning customers paying monthly or annually rather than buying a box. That matters because subscription revenue is far more predictable than one-time sales: a subscriber who paid last month is very likely to pay next month.

The segment telling the most interesting story is Document Cloud, the Acrobat and PDF business that most people think of as boring. That segment grew faster than the flagship Creative tools, and monthly active users for Acrobat and Express crossed hundreds of millions, up roughly a fifth from a year ago. That is not a mature, slow-moving business. That is a product finding a second gear.

BullScope TerminalYou just read ADBE’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

A business growing its fastest-expanding segment by double digits, with nearly all revenue locked into subscriptions, presents a different durability profile from one reliant on one-time sales, a distinction the filing makes measurable.

The number that compounds quietly

Remaining performance obligations, the total value of contracts customers have already signed but not yet received, reached $22.27 billion as of May 29, 2026. Think of it as a filled order book: revenue that is already sold and simply waiting to be delivered. That backlog is worth more than three full quarters of current sales, which means Adobe could stop signing new customers tomorrow and still be reporting revenue well into 2027. New customer signings are not guaranteed to continue at any particular pace, but the existing backlog alone establishes a meaningful revenue floor through mid-2027 under current contract terms.

Total annualized recurring revenue, the run-rate value of all active subscriptions, grew at a double-digit pace from a year ago. Within that, AI-first revenue, tied specifically to Adobe’s generative AI products, more than tripled year-over-year. Firefly, Adobe’s image and video generation tool built into Photoshop and Premiere, accounts for the largest share of that AI growth and accelerated sharply in a single quarter.

The honest complications

One quarter is one data point. The filing and the accompanying earnings commentary are candid about two genuine tensions.

First, Adobe is deliberately slowing its own near-term revenue to build long-term scale. The company is pushing Firefly and Acrobat into free tiers, letting users try before they pay. Management said this strategy will “materially” weigh on second-half growth. That is an honest trade-off: sacrifice some near-term subscription revenue to pull in millions of users who might convert to paid plans later. The math on whether that trade works won’t be visible for several quarters.

BullScope TerminalADBE was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

Second, operating margins slipped modestly from both a year ago and the prior quarter. A single quarter’s dip is not a trend, but it is worth watching. Analyst consensus, as reported by Zacks, remains a “Hold,” with concerns centered on leadership changes (the CFO departed in June 2026) and uncertainty about whether the freemium pivot converts users into payers at the hoped-for rate.

The risks are real and named, not buried in footnotes, a meaningful distinction when assessing whether a thesis rests on transparent or concealed assumptions.

Math vs. mood

“The math” is what filed fundamentals justify; “the mood” is what the market currently pays. Adobe’s math shows a price-to-earnings multiple near the lowest decile of its own decade-long history. The mood is deeply skeptical: the stock has fallen sharply over the past year and sits well below its recent peak. IF revenue continues at the filed trend AND margins hold near current levels AND the multiple reverts to its decade median of 31.5x (per BullScope valuation methodology), the arithmetic would point to a price in the range of approximately $500 to $540, a conditional illustration that depends entirely on the freemium bet paying off and leadership uncertainty resolving, both of which remain open questions and neither of which is assured.

Reading the numbers

  • $6.62 billion in Q2 revenue (13% year-over-year growth). What it is: total sales for the quarter ending May 29, 2026. What it means here: the growth rate is accelerating, not decelerating. Everyday version: a bakery that grew sales 10% last year and 13% this year is not slowing down.
  • $22.27 billion in remaining performance obligations. What it is: contracts already signed, revenue not yet recognized. What it means here: Adobe has a filled pipeline worth more than three quarters of current sales. Everyday version: a contractor who has signed enough jobs to keep the crew busy for the next year, regardless of new calls coming in.
  • AI-first ARR tripling to over $500 million. What it is: the annualized subscription value tied to AI products. What it means here: AI is no longer a talking point; it is a measurable revenue line. Everyday version: a restaurant that added a new menu section and watched it go from 5% of orders to 15% in one year.
  • P/E of 14.7 vs. decade median of 31.5 (trailing twelve-month earnings per SEC filings; median calculated per BullScope valuation methodology). What it is: the price-to-earnings multiple, or the price tag per dollar of annual profit, compared to Adobe’s own history. What it means here: the market is paying about half what it historically has for each dollar Adobe earns. Everyday version: a house in a neighborhood where similar homes sold for $600,000 for a decade, now listed at $280,000, an illustration of the valuation gap the market has assigned, the reasons for which remain debated.

For the standing yardsticks on Adobe: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Adobe.

Sources

  • Adobe 10-Q, quarter ended May 29, 2026 (SEC EDGAR)
  • Adobe Q2 FY2026 earnings release (Business Wire, June 11, 2026)
  • Adobe Q2 earnings beat, shares fall (Zacks via TradingView)
  • Adobe Q2 FY2026 earnings summary (VectorShift)
  • Adobe subscription model history (Dividend School)
  • What to expect from Adobe Q3 2026 (Barchart)
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read ADBE’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Arcutis: One Drug, Shrinking Losses, and a Label That Keeps Growing

by Moe Alsumidaie
October 23, 2026
0

For most of its life, Arcutis Biotherapeutics was a company with a single compelling bet: that a molecule called roflumilast, already proven in lung disease, could be reformulated...

Read moreDetails

One Drug, Nearly a Billion Dollars, and a Pipeline That Just Blinked

by Moe Alsumidaie
October 21, 2026
0

The short version Krystal Biotech built a profitable, cash-rich business on a single gene therapy approved just three years ago. The filed numbers show margins expanding sharply and...

Read moreDetails

Ardelyx: The Revenue Is Real, the Guidance Cut Is Realer

by Moe Alsumidaie
October 20, 2026
0

Three years ago, Ardelyx was burning through cash with almost nothing to show at the pharmacy counter. Then IBSRELA, its drug for irritable bowel syndrome with constipation, started...

Read moreDetails

Innoviva: The Royalties Are Shrinking. The Specialty Business Is Growing. Both Things Are True at Once.

by Moe Alsumidaie
October 20, 2026
0

Innoviva spent most of its life as a toll booth on two GSK inhalers. Every time a patient filled a BREO or ANORO prescription, Innoviva collected a royalty...

Read moreDetails

One Drug Is Carrying the Weight. Two Acquisitions Just Added More.

by Moe Alsumidaie
October 19, 2026
0

Three years ago, Tarsus Pharmaceuticals was shrinking. Revenue had fallen by more than half in 2022, then fell again in 2023, and the company was burning through cash...

Read moreDetails
Next Post

The Price That Needs a Perfect Harvest

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Regeneron ties executive pay to pipeline output, not revenue growth, signaling confidence in R&D engine

October 1, 2026

Evidence Sheet: Organon & (OGN)

September 2, 2026

Moderna at 28 Times Sales: One Trial Result Is Doing a Lot of Work

September 3, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.